20.500.12556/DiRROS-18736 Aggressive anticancer treatment in the last 2 weeks of life Background: There is a concern that terminally ill cancer patients may be aggressively treated due to the rapidly growing possibilities of anticancer treatment. The aim of this study was to evaluate the use of anticancer treatment at the end of life (EoL). Materials and methods: This retrospective study included adult patients with advanced solid cancers who were treated at the Institute of Oncology Ljubljana and died of cancer between January 2015 and December 2019. A multiple logistic regression model was used to assess an association between the aggressiveness of anticancer treatment (i.e. systemic therapy, radiotherapy and surgery) in the last 2 weeks of life and year of death, age at death, sex, prognosis of cancer and enrolment into the specialist palliative care (SPC). Results: We included 1736 patients in our analysis. Overall, 13.7% of patients were enrolled into the SPC and 14.4% received anticancer treatment in the last 2 weeks of life. The odds of receiving anticancer treatment significantly increased over time [odds ratio (OR) 1.15, 95% confidence interval (CI) 1.04-1.27]. There was an increased use of novel systemic therapy (e.g. small-molecule targeted therapy and immunotherapy) at the EoL. Older patients had significantly lower odds to receive anticancer treatment in the last 2 weeks of life as compared to younger patients (OR 0.96, 95% CI 0.95-0.98). As compared to patients receiving only a standard oncology care, those also enrolled into the SPC had significantly lower odds for anticancer treatment in the last 2 weeks of life (OR 0.22, 95% CI 0.12-0.43). Conclusions: Terminally ill cancer patients have increased odds for receiving anticancer treatment, especially novel systemic therapies, in the last 2 weeks of life. Younger patients and those not enrolled into the SPC are at particular risk for anticancer treatment at the EoL systemic therapy aggressive treatment anticancer drugs palliative care sistemsko zdravljenje onkološka zdravila agresivno zdravljenje paliativna oskrba true false true Elsevier Amsterdam Angleški jezik Slovenski jezik by Authors Neznano 2024-04-18 13:39:47 2024-04-18 13:39:48 2024-05-14 11:09:15 0000-00-00 00:00:00 2024 0 0 Nasl. z nasl. zaslona; Opis vira z dne 18. 4. 2024; str. 102937-1-102937-8 iss. 3 Vol. 9 Mar. 2024 0000-00-00 Zaloznikova Objavljeno apc 0000-00-00 0000-00-00 2024-03-11 616-006 2059-7029 10.1016/j.esmoop.2024.102937 189297923 https://www.sciencedirect.com/science/article/pii/S2059702924007051?via%3Dihub 1 9a4a2c00-fd67-11ee-ae20-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=25637 RAZ_Golob_Nena_2024.pdf RAZ_Golob_Nena_2024.pdf 1 F6C5350A018D2D4044D19C4B7B15CC54 70d975fe0fc3cbe3b4587d113d68d5533f7f7165269e5fc1f740ca8742dd54f4 51d8b36a-fd69-11ee-ae20-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=25638 Onkološki inštitut Ljubljana 0 0 0